Q-omics provides the consensus-scored ANTKMT profile across patient tissues and cancer cell-line models. ANTKMT expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ANTKMT is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, ANTKMT RNA expression shows 18,680 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, COAD, and THYM as cancer lineages where ANTKMT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANTKMT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANTKMT survival associations across molecular data types. ANTKMT RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANTKMT RNA expression–survival associations across cancer types. High ANTKMT expression shows unfavorable associations in UVM, UCS, ACC, LUAD and KIRC, but favorable associations in HNSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify HNSC as the clearest survival context for ANTKMT RNA expression.
This table summarizes ANTKMT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ANTKMT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANTKMT shows higher tumor expression in COAD, HNSC, LIHC, BLCA, KIRP and LUAD. The COAD box plot shows higher ANTKMT RNA expression in tumor versus normal tissue (log2 FC = +1.214, t-test p < 0.001).
This table shows molecular features associated with ANTKMT in patient tissues and cancer cell lines. In patient samples, ANTKMT shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ANTKMT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BONE and SOFT_TISSUE.
